Jasmine Zain, MD
Hematology · Duarte, CANPI 1043327075
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Kyowa Kirin, Inc. at 41.1% of the total. Reporting peaked in 2021 at $24,391 and has fallen 92.0% since, to $1,952 in 2025.
Across 94 payments — averaging $865.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$33K
- Seagen Inc.$16K
- Kyowa Kirin Services Ltd$15K
- Secura Bio, Inc.$6K
- Acrotech Biopharma Inc.$5K
- Verastem, Inc.$3K
- plus $3K from 13 others
Across 164 payments — averaging $12,557 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$655K
- AbbVie$469K
- Astrazeneca UK Limited$286K
- Secura Bio, Inc.$255K
- Seagen Inc.$116K
- Merck$72K
- plus $206K from 5 others
What the payments were for
- Consulting fees$46,76857%
- Speaking & faculty fees$28,58635%
- Travel & lodging$2,4383%
- Food & beverage$3,5594%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 32 | $33,423 |
| Seagen Inc. | 24 | $16,021 |
| Kyowa Kirin Services Ltd | 8 | $15,313 |
| Secura Bio, Inc. | 7 | $6,081 |
| Acrotech Biopharma Inc. | 3 | $4,659 |
| Verastem, Inc. | 3 | $2,833 |
| Daiichi Sankyo Inc. | 1 | $2,096 |
| Genmab U.S., Inc. | 2 | $213 |
| Morphosys, US Inc. | 1 | $138 |
| Helsinn Therapeutics (U.S.), Inc. | 4 | $120 |
| Gilead | 1 | $120 |
| Pfizer | 1 | $82 |
| Genentech USA, Inc. | 1 | $79 |
| Beigene USA, Inc. | 1 | $62 |
| ADC Therapeutics America, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| AbbVie | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Amgen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,352 in reported general payments places this provider in the 80th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nystatin | 14 | $294 |
| Acyclovir | 15 | $71 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $55 |
| Prednisone | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.